Xgeva is used in men with advanced and metastatic prostate cancer with bone metastases for the prevention of developing additional skeletal-related events (not to be confused with bone mineral density). In a phase 3 trial, the 147 Study, evaluating denosumab (Xgeva) versus placebo 1,432 men with castrate-resistant prostate cancer demonstrated that Xgeva improved median bone [...]
We have long known that Zoledronic Acid (Zometa) decreases a man’s risk of developing skeletal-related events (SREs) in men with castration-resistant advanced prostate cancer (CRPC) and bone metastases. In a phase III study that evaluated efficacy and safety of earlier treatment with Zometa in men with advanced prostate cancer which is still castration-sensitive found that [...]
I recently made a video with Dr. James Mckiernan of Columbia Presbyterian Hospital in New York City on the use of Zometa (zoledronic acid) to combat bone metastases in advanced prostate cancer that is castrate resistant. Novartis Oncology, the makers of Zometa, sponsored the video and it was produced on the Wego Health web page. [...]
